Expression of microribonucleic acid 1228 in inflammatory bowel disease patients

Introduction Knowledge in the field of microribonucleic acids (miRNAs) can be used both to reveal the mechanisms of occurrence of inflammatory bowel diseases (IBDs) and to predict the response to a particular treatment. Aim The aim of this article is to assess the serum expression of miR-1228 in IBD patients. Materials and Methods A total of 35 patients with ulcerative colitis (UC), 35 patients with Crohn’s disease (CD), and a control group of 30 healthy individuals were studied. Serum expression of miR-1228 was tested in all through reverse transcriptase-quantitative real-time polymerase chain reaction (RT-qPCR). Results The expression in CD patients (1.91 ±2.21) was significantly higher compared to the expression in UC patients (1.15±0.64) and healthy controls (1.14±0.59). In CD patients, increased expression of miR-1228 was observed in cases with active disease, intestinal localization (L1–2.28) and penetrating phenotype (B3–3.92). In UC patients, no difference in miR-1228 expression was observed with regards to the localization and the course of the disease. Serum expression of miR-1228 correlates positively with CRP in UC patients. Conclusion In the present study, increased expression of miR-1228 was observed in cases with active disease (UC, CD), intestinal localization (CD), and penetrating phenotype (CD), while decreased expression correlated to immunosuppressive (CD) and biological (UC) therapy.